GlobeNewswire Inc.··Argenx Seargenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial
argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial